Onchocerciasis, Ocular: Clinical Trials

7 trials for Onchocerciasis, Ocular, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Onchocerciasis, Ocular: new trials by email Literature Review of Onchocerciasis, Ocular trials Research Report on Onchocerciasis, Ocular

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis
Phase 2Active not recruitingWashington University School of Medicine3002024-04-052025-12-18
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis
Phase 2CompletedCenter for Research on Filariasis and Other Tropical Diseases, Cameroon722022-04-072025-02-24
Emodepside Phase II Trial for Treatment of Onchocerciasis
emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis
Phase 2UnknownDrugs for Neglected Diseases5782021-08-302024-03-05
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis
Phase 2TerminatedAbbVie1532021-05-222024-09-19
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis
Phase 2CompletedProgramme National de Lutte contre l'Onchocercose, Republic of the Congo2552021-01-162021-09-20
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
moxidectin - Onchocerciasis
Phase 2WithdrawnPfizer2011-04-012012-03-29
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
2 mg moxidectin, ivermectin 150 mcg/kg, 4 mg moxidectin - Onchocerciasis
Phase 2CompletedMedicines Development for Global Health1722006-09-062022-12-15

Narrower conditions

Onchocerciasis (5)  ·  Loiasis (2)  ·  Filariasis (1)  ·  Helminthiasis (1)  ·  Neglected Diseases (1)  ·  Nematode Infections (1)  ·  Parasitic Diseases (1)  ·  Skin Diseases (1)  ·  Skin Diseases, Infectious (1)  ·  Skin Diseases, Parasitic (1)

Broader conditions

Eye Diseases (7)  ·  Eye Infections (7)  ·  Eye Infections, Parasitic (7)  ·  Infections (7)  ·  Secernentea Infections (7)  ·  Spirurida Infections (7)  ·  Vector Borne Diseases (7)  ·  Filariasis (6)  ·  Helminthiasis (6)  ·  Nematode Infections (6)  ·  Parasitic Diseases (6)  ·  Skin and Connective Tissue Diseases (5)  ·  Skin Diseases (4)  ·  Skin Diseases, Infectious (4)  ·  Skin Diseases, Parasitic (4)

Interventions

Ivermectin (4)  ·  moxidectin (4)  ·  Albendazole (2)  ·  Bay 44-4400 (1)  ·  Diethylcarbamazine (1)  ·  Levamisole (1)  ·  Tablets (1)  ·  emodepside (1)

Sponsors

AbbVie (1)  ·  Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1)  ·  Drugs for Neglected Diseases (1)  ·  Medicines Development for Global Health (1)  ·  Pfizer (1)  ·  Programme National de Lutte contre l'Onchocercose, Republic of the Congo (1)  ·  Washington University School of Medicine (1)

Countries

Democratic Republic of the Congo (2)  ·  Ghana (2)  ·  Cameroon (1)  ·  Liberia (1)  ·  Republic of the Congo (1)

Top investigators

Gary Weil, MD (1)  ·  Nicholas Opoku, MD (1)  ·  Patrick Kpanyen, PhD (1)  ·  Peter Fischer, PhD (1)

Results publications

PMID 24968000, PMID 34651190, PMID 38966851